PRETREATMENT OF DONOR BONE MARROW WITH MONOCLONAL ANTIBODY OKT3 FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HISTOCOMPATIBLE BONE-MARROW TRANSPLANTATION
- 31 May 1982
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 319 (8284) , 1266-1269
- https://doi.org/10.1016/s0140-6736(82)92840-9
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- USE OF ANTI-T-CELL MONOCLONAL ANTIBODY OKT3 TO PREVENT ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR ACUTE LEUKAEMIAThe Lancet, 1982
- A Randomized Study of the Prevention of Acute Graft-versus-Host DiseaseNew England Journal of Medicine, 1982
- Nephrotoxicity of Cyclosporin a after Allogeneic Marrow TransplantationNew England Journal of Medicine, 1981
- FAILURE OF EARLY ADMINISTRATION OF ANTITHYMOCYTE GLOBULIN TO LESSEN GRAFT-VERSUS-HOST DISEASE IN HUMAN ALLOGENEIC MARROW TRANSPLANT RECIPIENTSTransplantation, 1981
- Identification of a human T lymphocyte surface protein associated with the E-rosette receptor.The Journal of Experimental Medicine, 1981
- CYCLOSPORIN A TO PREVENT GRAFT-VERSUS-HOST DISEASE IN MAN AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATIONThe Lancet, 1980
- Monoclonal Antibodies Defining Distinctive Human T Cell Surface AntigensScience, 1979
- CYCLOSPORIN A FOR THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE IN MANThe Lancet, 1978
- Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow.The Journal of Experimental Medicine, 1978
- Human bone marrow colony growth in agar‐gelJournal of Cellular Physiology, 1970